DiCarta

DiaCarta operates as a precision molecular diagnostics company, focusing on the development of technologies for oncology and infectious diseases. The firm was established in 2011 by Aiguo (Adam) Zhang, Ph.D., who currently serves as the President and CEO. Dr. Zhang possesses extensive experience in the biotech and pharmaceutical sectors, having worked with companies like Affymetrix and Bio-Rad, which provides him with a strong background in R&D management and a network in Asian and emerging markets.

The company's business model centers on providing highly sensitive diagnostic solutions to healthcare providers, laboratories, and pharmaceutical partners. Its revenue is generated through the sale of diagnostic test kits and the provision of CLIA-certified laboratory testing services. DiaCarta targets the global healthcare market, aiming to improve patient outcomes by enabling early and accurate disease detection and monitoring. In October 2022, the company announced a definitive business combination agreement with HH&L Acquisition Co., a special purpose acquisition company (SPAC), with the expectation of becoming a publicly listed company on the New York Stock Exchange. This transaction implied a pre-money equity value of $460 million for DiaCarta. To date, the company has raised a total of $53 million in funding over three rounds, with the latest being a $45 million Series B round in February 2018, led by Fortune Fountain Capital.

DiaCarta's product portfolio is built upon its proprietary technology platforms, including XNA and SuperbDNA™, which enhance the sensitivity of detecting genetic alterations from liquid biopsy samples like blood. A key offering is the ColoScape™ test, a highly sensitive assay for detecting colorectal cancer from both liquid biopsy and tissue samples. Another product, RadTox™, is a cfDNA test used to personalize radiation and chemotherapy by assessing tumor response. The company also developed the FDA EUA-approved QuantiVirus™ test for SARS-CoV-2 and has expanded its infectious disease line to include tests for HPV and mpox. These products are designed to deliver superior clinical performance and economic value, serving a critical need for non-invasive and reliable diagnostic tools in modern healthcare.

Keywords: molecular diagnostics, precision diagnostics, liquid biopsy, oncology testing, infectious disease tests, cancer detection, Aiguo Zhang, ColoScape, RadTox, XNA technology, colorectal cancer screening, cfDNA test, personalized medicine, CLIA laboratory, translational genomics, qPCR tests, NGS panels, in vitro diagnostics, tumor response monitoring, SuperbDNA